Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 27241-155

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 27241-155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxybutynin-10mg (Oxybutynin 10mg)

Label for Oxybutynin Chloride Extended-Release Tablets, USP 10 mg, oral tablets, containing 100 tablets per bottle. Marketed by Ajanta Pharma USA Inc. The label includes storage instructions, dosage reference, and child-resistant packaging information. The NDC number 27241-156-04 is visible along with a barcode.*

FDA Label Image

Oxybutynin-15mg (Oxybutynin 15mg)

Label for Oxybutynin Chloride extended-release tablets, USP, 15 mg strength. The label indicates a count of 100 tablets, oral route, marketed by Ajanta Pharma USA Inc. Storage instructions specify 20°C to 25°C with permitted excursions. The package is child-resistant and states it is made in India.*

FDA Label Image

Oxybutynin-5mg (Oxybutynin 5mg)

Label for Oxybutynin Chloride Extended-Release Tablets, USP, 5 mg strength, oral tablet dosage form. The package contains 100 tablets and is marketed by Ajanta Pharma USA Inc. Storage instructions specify 20-25°C with allowed excursions. The label notes the product is child-resistant and made in India.*

FDA Label Image

Figure1 (Oxybutynin Figure1)

A line graph comparing mean plasma R-Oxybutynin concentration (ng/mL) over 24 hours for oxybutynin chloride extended-release tablets 10 mg once daily versus 5 mg three times daily dosing. The x-axis shows time in hours, and the y-axis shows plasma concentration. Two data sets with error bars depict concentration fluctuations for both dosing regimens.*

FDA Label Image

Figure2 (Oxybutynin Figure2)

A line graph depicting mean roxybutynin plasma concentration (ng/mL) over a 24-hour period. The x-axis represents time in hours, and the y-axis shows plasma concentration levels, with data points connected by a line and error bars indicating variability.*

FDA Label Image

Figure3 (Oxybutynin Figure3)

A chart comparing Oxybutynin Chloride Extended Release Tablets with placebo. The horizontal axis ranges from -40 to 40, showing data points for both Oxybutynin Chloride Extended Release Tablets and placebo with confidence intervals. The chart likely represents a clinical or pharmacological comparison.*

FDA Label Image

Figure4 (Oxybutynin Figure4)

A chart showing a plotted point with error bars labeled for oxybutynin and oxybutynin chloride extended-release tablets along a horizontal axis ranging approximately from -40 to 40. The chart appears to compare values or measurements related to oxybutynin derivatives.*

FDA Label Image

Figure5 (Oxybutynin Figure5)

A horizontal bar chart comparing two items labeled 'Oxybutynin Chloride Extended-Release Tablets' and 'oxybutynin' on a numerical scale ranging from -40 to 40, with bars extending into the negative range. The chart visually contrasts these two categories across the same quantitative axis.*

FDA Label Image

Oxybutynin-structure (Oxybutynin Structure)

Chemical structure of oxybutynin chloride. The diagram displays the molecular arrangement including aromatic rings, ester, alkyne, amine groups, and a hydrochloride component typical for this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.